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Fusarium is a geophilic fungus, widely distributed in soil all
around the world. Pathogenic subtypes may cause opportunistic
infections in humans, particularly in patients with underlying
immunosuppression.
We have encountered disseminated fusariosis in three patients
(case 1: a 46-year-old male; case 2: a 50-year-old female; case 3: a
33-year-old female), who had undergone allogeneic hematopoi-
etic stem cell transplantation (HSCT). The infection developed
37, 60 and 75 days after HSCT, respectively. All patients had
prolonged (>10 days) and profound (<100/mm3) neutropenia
and presented with persistent high fever refractory to broad-
spectrum antibiotics. Dermatologic examination revealed tender
purpuric targetoid macules and plaques with central necrotic
eschars. The cutaneous eruption displayed an abrupt onset and
an accelerated course with eventual widespread dissemination to
trunk, head and extremities (Figs 1 and 2c). Histopathological
examination in all cases revealed fungal septated and branched
hyphae and yeasts in the dermis between the collagen fibres and
within the blood vessels. PAS stain highlighted the fungal ele-
ments (Fig. 2a). Fusarium spp were isolated from fungal culture
on days 69, 75 and 110, respectively (Fig. 2b). After the diagno-
sis was firmly established as fusariosis, a combination of intra-
venous voriconazole (first day 6 mg/kg twice daily, then 4 mg/
kg twice daily) and liposomal amphotericin B (5 mg/kg/day)
was introduced. Unfortunately, this therapy could not halt the
progression of the infection and patients succumbed to disease
at 72, 118 and 137 days after HSCT, respectively.
Fusariosis in the immunocompromised population is typi-
cally an invasive or disseminated infection with a poor outcome.
In contrast to other fungal infections, fusarium stands out with
its ability to cause fungemia. The mortality rate usually ranges
from 60% to 80%. Fusariosis is the second most common inva-
sive mould infection in HSCT recipients.1,2 Figures on the inci-
dence of invasive fusariosis in allogeneic HSCT recipients are
varied: 0.2% in USA,3 3% in Italy4 and 5.2% in Brazil.5 We have
encountered four cases among 417 allogeneic HSCT recipients
within 8 years; the incidence was 0.9% in our experience.
Among the numerous underlying risk factors for fusariosis,
the principal ones are neutropenia and impaired T-cell function.
All patients described herein had received calcineurin inhibitors
and high-dose steroids (as a prophylaxis for graft versus host
disease), which powerfully inhibit T-cell function. In addition,
all of them had impaired neutrophil engraftment as the cause of
their neutropenia, which is another risk factor for fusariosis.
The major portal of entry for Fusarium spp is the airways, fol-
lowed by skin at sites of tissue breakdown, and possibly the
mucous membranes. It has been disclosed that the hospital
plumbing system may be a reservoir for Fusarium spp.6 All
patients in this report had severe mucositis on admission, which
might represent the portal of entry for the infection.
The typical clinical scenario for fusariosis comprises abrupt
onset of painful purpuric macules, patches and plaques with
central necrosis, in a severely neutropenic patient with high
fever. Targetoid lesions may simulate ecthyma gangrenosum or
purpura fulminans. We have also observed radial fresh purpuric
globules around targetoid necrotic lesions (Fig. 1).
Accurate diagnosis of fusariosis may be accomplished through
blood culture, skin biopsy, fungal culture, PCR and 1,3-beta-D-
glucan antigen testing. Although fungal culture is a prerequisite
for precise diagnosis of fusariosis, skin biopsy is the quickest and
Figure 1 Ecthyma gangrenosum-like lesions were noted in two of
our patients with fusariosis (Case 1 and case 3).
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easiest way for a presumptive diagnosis until the culture results
are available.7
The optimal treatment for invasive fusariosis is unclear. Nucci
et al.7 recommend either voriconazole or liposomal ampho-
tericin B as primary therapy, despite occasional rewarding out-
comes. The most important positive prognostic factor is
resolution of neutropenia.
In conclusion; disseminated fusariosis should be considered
in all patients presenting with high fever and widespread targe-
toid purpuric and necrotic cutaneous lesions, in the context of
profound and protracted neutropenia and/or T-cell dysfunction.
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Effectiveness and adverse
events of ivermectin treatment
for scabies in 30 infant patients:
report from a German single
centre
Dear Editor,
Scabies is a globally prevalent parasitic skin infestation charac-
terized by severe pruritus and a heterogeneous clinical picture
depending on the immune status of the individual. Epidemio-
logic studies reveal a higher susceptibility for young, old and, in
general, immunocompromised individuals. Disease-related mor-
bidity and secondary complications due to a disrupted epider-
mal barrier, e.g. subsequent bacterial infections and chronic
kidney disease, further add to the patients’ burden.1 With cur-
rent treatment options, induction of remission is achieved in
most of the patients. Specifically, the oral administration of iver-
mectin has substantially decreased the prevalence of scabies in
communities and has proven to be effective and tolerable.2,3
However, relapses in larger families are frequent and ivermectin
is not approved for children <15 kg. Hence, evaluation of the
safety of ivermectin use in infants is highly warranted. Recently,
a multicentric observational study has reported on the safety and
efficacy of ivermectin use in infants weighing <15 kg4. 85% of
170 patients achieved remission and in 4% of the patients, mild
adverse effects were observed. However, safety of ivermectin
remains controversial,5,6 and controlled studies in infants are
scant.7,8 We therefore retrospectively analysed 30 infants <15 kg
infected with scabies. The patients were treated off-label with
oral ivermectin under controlled and standardized conditions
during hospitalization between 01/2018 and 01/2020. The focus
of our observation was on safety and efficacy. This study was
approved by the local ethics committee.
After informed consent by the legal guardian(s), 30
patients [age (months), mean  SD: 12  9.2; weight (kg),
mean  SD: 8.6  2.5, 16 males, 14 females] were treated
with oral ivermectin after clinical and dermatoscopic diagno-
sis of scabies. All patients had been unsuccessfully treated
with topical permethrin at least twice prior to ivermectin
administration and were at least 2 months of age. Prior
topical treatment with permethrin creme 5% was applied
overnight on the entire body, including the head and neck,
at days 0 and 7. Concomitantly, all individuals with close
physical contact to the scabies-infected patient received
appropriate scabies treatment. Supportively, recommended
hygienic measures were applied. A relapse was defined as a
recurrent clinical skin manifestation caused by scabies mites
as detected by dermatoscopy 4 weeks after treatment. Rea-
sons for relapses in these patients remain speculative; how-
ever, they might be explained either by (i) a lack of efficacy
of the topical permethrin treatment or by (ii) the insuffi-
cient application in an outpatient setting. At days 0 and 7,
ivermectin capsules were orally applied at a dose of 200 lg
per kg bodyweight; concomitantly, topical permethrin 5%
treatment was applied. To monitor safety, all patients were
hospitalized for at least 2 days and blood samples were
obtained, in total for 4 times, specifically, before and 24 h
after ivermectin administration both at days 0 and 7. To
determine ivermectin-related pathological changes, findings
in blood samples collected before ivermectin treatment were
used as a reference and were compared to results in blood
samples obtained after ivermectin treatment. In most cases,
final clinical and dermatoscopic examination was performed
at a follow-up visit on day 14.
After treatment, 4 patients (2/4 at day 1 and 2/4 at day 8)
revealed slightly elevated creatine kinase levels but no further
pathological findings in the routine laboratory examination. No
severe-grade 2–5 adverse events were observed. A total of 21
patients showed no detectable mites and regredient inflamma-
tory skin lesions. Four additional patients did not return to our
clinic but were contacted by telephone and confirmed clinical
remission. In 5 patients, we lost follow-up.
While our study provides first insights into the safety and effi-
cacy of oral ivermectin in infants in Germany, the findings need
to be interpreted within the limitations of the study, specifically,
(i) the retrospective study design, (ii) the focus on a single centre
and (iii) the limited sample size. In addition to the question-
naire-based multicentre study on 170 patients performed by Levy
et al.,4 we here provide a safety monitoring under controlled
inpatient conditions and based on routine blood examination.
Despite the limitations of our study, our observations suggest
the safe and effective use of ivermectin in infants <15 kg infected
with scabies and warrant the initiation of a prospective con-
trolled study for this indication.
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